Hepatitis C DNA vaccine - Pharmexa-Epimmune
Latest Information Update: 27 Feb 2008
At a glance
- Originator Pharmexa-Epimmune
- Class Antivirals; DNA vaccines; Hepatitis C vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 18 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma
- 30 Aug 2002 This vaccine is still in active development
- 01 Mar 1999 Preclinical development for Hepatitis C in USA (Unknown route)